Provided by Tiger Trade Technology Pte. Ltd.

CANSINOBIO

26.840
-1.820-6.35%
Volume:3.98M
Turnover:107.82M
Market Cap:6.63B
PE:244
High:28.400
Open:28.260
Low:26.640
Close:28.660
52wk High:55.850
52wk Low:19.220
Shares:247.04M
HK Float Shares:132.67M
Volume Ratio:0.68
T/O Rate:3.00%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.110
ROE:0.82%
ROA:-0.60%
PB:1.14
PE(LYR):244.00
PS:4.60

Loading ...

AH Share Premium and Deviation Data for July 20th

Stock News
·
Jul 20

CANSINOBIO Shares Surge on Regulatory Progress for Meningitis Vaccine

Stock News
·
Jul 20

CanSino Biologics Gets NMPA Nod to Review Supplemental Application Expanding Menhycia® Age Range

Bulletin Express
·
Jul 19

CansinoBIO Receives NMPA Acceptance for Age Extension of MenQuad Vaccine

Stock News
·
Jul 19

AH Share Premium and Deviation Rankings as of July 13th Close

Stock News
·
Jul 13

CANSINOBIO Sees Stable Share Capital in June 2026; Public Float Meets HKEX Requirement

Bulletin Express
·
Jul 03

AH Share Premium and Deviation Rankings for July 3rd

Stock News
·
Jul 03

CanSino Biologics Gets Registration Certificate for Meningitis Vaccine in Argentina

MT Newswires Live
·
Jun 25

CanSino Biologics: MCV4 Vaccine Gains Argentine Registration, Advancing Global Strategy

Bulletin Express
·
Jun 25

CansinoBIO Secures Regulatory Approval in Argentina for Meningococcal Vaccine

Stock News
·
Jun 25

CanSino Biologics Defines Governance, Capital Structure and Dividend Policy in Updated Articles of Association

Bulletin Express
·
Jun 10

CANSINOBIO Keeps Share Capital Steady in May; 2.91 Million Shares Reserved for Incentive Plans

Bulletin Express
·
Jun 02

CanSino Biologics Begins Trials of Broad Pneumococcal Conjugate Vaccine

MT Newswires Live
·
May 26

CANSINOBIO (06185) Initiates Phase I/II Clinical Trial for PCV24 with First Participant Enrolled

Stock News
·
May 26

CANSINOBIO Initiates Phase I/II Trial of 24-Valent Pneumococcal Conjugate Vaccine PCV24, Enrolls First Patient

Bulletin Express
·
May 26

CANSINOBIO Sets 2025 AGM for 10 June 2026; Seeks Share-Issuance, Repurchase and Dividend Mandates

Bulletin Express
·
May 19

CANSINOBIO Calls 10 June 2026 AGM to Approve 2025 Results, No Dividend Payout, and Fresh Financing Mandates

Bulletin Express
·
May 19

CanSino Biologics' Drug Application for Combined Vaccines Granted Priority Review in China

MT Newswires Live
·
May 11

CansinoBIO's Td5cp Vaccine for Adolescents and Adults Granted Priority Review by China's Drug Regulator

Stock News
·
May 11

CanSino Biologics Q1 Loss After Two Profitable Quarters Tests Bullish Profitability Narratives

Simply Wall St.
·
Apr 30